Open AccessPosaconazole
Author(s) -
Maitreyee Bhattacharya,
K Rajeshwari,
Bhavna Dhingra
Publication year - 2010
Publication title -
journal of postgraduate medicine/journal of postgraduate medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 52
eISSN - 0972-2823
pISSN - 0022-3859
DOI - 10.4103/0022-3859.65281
Subject(s) - posaconazole , medicine , aspergillosis , antifungal , incidence (geometry) , adverse effect , esophageal candidiasis , invasive candidiasis , intensive care medicine , dermatology , amphotericin b , fluconazole , immunology , human immunodeficiency virus (hiv) , viral disease , physics , optics
Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents.